A Smart Approach to Treating Tobacco Use Disorder in Persons Living With

Status Active, not recruiting

Clinical Trial Summary

Many people living with HIV (PLWH) smoke. Smoking in these individuals is often undertreated. This study plans to assess the ability of various clinical pathways involving tobacco treatment medications and contingency management (paying smokers for not smoking) to improve smoking cessation in a group of PLWH.

Clinical Trial Description

Using a Sequential Multiple Assignment Randomized Trial (SMART) design, this project is a two-arm, two-stage randomized trial of 320 adult PWH who smoke cigarettes and receive care in one of three health systems (targeted enrollment changed from 632 to 320 with NCI approval and IRB protocol amendment). At inception, participants will be randomized to either combination nicotine replacement therapy (NRT, patch + short-acting NRT) or combination NRT+contingency management (CM). At 12 weeks, responders (non-smoking participants confirmed by exhaled carbon monoxide [eCO] or collateral verification) in both arms will receive 12 more weeks of the same treatment. Non-responders (participants with continued smoking by self-report and/or eCO) in both the NRT and NRT+CM arms will be re-randomized to 12 weeks of treatment, either with medication switch to oral medication, varenicline or bupropion, or intensified level of CM (start CM if no CM during first 12 weeks, or CM with higher reward schedule ["CM plus"] if NRT+CM group initially). The intervention will be delivered by trained clinical pharmacists. The primary outcome will be self-reported abstinence at 24 weeks post-enrollment (primary outcome changed from eCO-confirmed abstinence to self-reported abstinence with NCI approval and IRB protocol amendment). The specific aims of the proposed study are to: (1) identify the optimal adaptive approach to promote reduced tobacco use (changed from eCO-confirmed smoking abstinence with NCI approval and protocol amendment) (2) study the effectiveness of various adaptive strategies on CD4 count, HIV viral suppression, and VACS index (validated measure of morbidity and mortality risk); and (3) grounded in implementation science and using aHybrid Effectiveness-Implementation Type I design, identify barriers and facilitators to delivering our intervention to inform future implementation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04490057
Study type	Interventional
Source	Yale University
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	July 27, 2020
Completion date	September 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06021652` - Feasibility, Adoption and Efficacy of A Virtual Reality Smoking Cessation Program for Patients Undergoing Lung Cancer Screening	N/A
Completed	`NCT02735382` - EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study	N/A
Completed	`NCT02557919` - Families Reduce Exposure to Smoke at Home	N/A
Completed	`NCT01570595` - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV	Phase 1/Phase 2
Completed	`NCT00786149` - Improving Varenicline Adherence and Outcomes in Homeless Smokers	Phase 3
Completed	`NCT00387946` - Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)	Phase 3
Completed	`NCT00218452` - Smoking Cessation for Young Adults Who Binge Drink - 1	Phase 0
Completed	`NCT00124683` - Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1	Phase 2
Recruiting	`NCT04610931` - Study of the Effectiveness of a Virtual Reality Treatment in the Management of Smoking Cessation	N/A
Enrolling by invitation	`NCT06042361` - Enhancing Equity in Smoke-free Housing	N/A
Recruiting	`NCT04994444` - Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts	Phase 2/Phase 3
Recruiting	`NCT04827420` - Mi QUIT CARE (Mile Square QUIT Community-Access-Referral-Expansion)	N/A
Completed	`NCT05560243` - Tobacco Cessation Tailored to Patients Living With HIV (PLWH) in Brazil	N/A
Completed	`NCT02721082` - Changing the Default for Tobacco Treatment	Phase 4
Completed	`NCT01885221` - A Multi-Media Approach to Partner Support in Smokeless Tobacco Cessation (UCare-ChewFree)	N/A
Completed	`NCT03445507` - Effectiveness of a Chat Bot for Smoking Cessation: a Pragmatic Trial in Primary Care.	N/A
Completed	`NCT04540081` - Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer	N/A
Completed	`NCT03714191` - Optimizing the Tobacco Cessation Clinical Decision Support Tool.
Completed	`NCT03553992` - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers	N/A
Completed	`NCT01699828` - Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV — SMARTTT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms